Related Experiment Video
Updated: Aug 23, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
Published on: June 23, 2011
Development of bivalent rgp120 vaccines to prevent HIV type 1 infection
1VaxGen, Inc., South San Francisco, California 94080, USA. pwb@gene.co
Abstract:
A new generation of "bivalent" gp120-based vaccines, effective against subtype B and subtype E viruses, has been developed. Antisera from rabbits and humans immunized with these vaccines are able to neutralize macrophage tropic and T-cell tropic viruses grown in activated peripheral blood mononuclear cells (PBMCs). These vaccines are now available for efficacy trials to determine the role of humoral immunity in providing protection against human immunodeficiency virus type 1 (HIV-1) infection.
More Related Videos
13:36Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
10:58Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
Related Concept Videos
Respiratory Syncytial Virus Disease
Inhibitors of Virion Maturation and Assembly